Results 61 to 70 of about 2,351 (180)

Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma ...
Zhe Wang   +3 more
wiley   +1 more source

Editorial: 2022 in review: allergen immunotherapy [PDF]

open access: yesFrontiers in Allergy
Linda Cox   +3 more
doaj   +2 more sources

Use of Immunotherapy in the Treatment of Peanut Allergies in the Pediatric Population [PDF]

open access: yes, 2015
Peanut allergies are a serious issue that must be monitored and treated effectively to avoid severe adverse effects and death. In the last decade, their incidence has increased significantly, due to indeterminate factors.
Rauscher, Bethany
core  

Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk‐Treatment Protocol

open access: yesAllergy, EarlyView.
A revised milk OIT protocol with lower daily allergen load and slower dose escalation reduced the severity and delayed onset of OIT‐induced gastrointestinal eosinophilic reactions (OITIGER). Elevated baseline absolute eosinophil count (AEC > 600/μL) was a consistent independent risk factor for OITIGER, while older age was protective.
Na'ama Epstein‐Rigbi   +8 more
wiley   +1 more source

Skin exposure promotes a Th2-dependent sensitization to peanut allergens [PDF]

open access: yes, 2013
Sensitization to foods often occurs in infancy, without a known prior oral exposure, suggesting that alternative exposure routes contribute to food allergy.
Tordesillas, Leticia   +8 more
core   +1 more source

A Systematic Review and Meta‐Analysis on the Induction of Confirmed Eosinophilic Esophagitis as a Side Effect of Allergen Immunotherapy: An EAACI Task Force Report

open access: yesAllergy, EarlyView.
ABSTRACT The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta‐analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or ...
Carlo Maria Rossi   +14 more
wiley   +1 more source

Efficacy of Epicutaneous Immunotherapy in Children With Milk-Induced Eosinophilic Esophagitis [PDF]

open access: yesClinical Gastroenterology and Hepatology, 2020
Eosinophilic esophagitis (EoE) is caused by an immune response to specific food allergens. There are no approved therapies beyond avoidance of the allergen(s) or treatment of inflammation. Epicutaneous immunotherapy (EPIT) reduces features of eosinophilic gastrointestinal disease in mice and pigs.
Jonathan M, Spergel   +8 more
openaire   +2 more sources

Novel Approaches to Allergen Immunotherapy for Respiratory Allergies

open access: yesPharmaceuticals
Allergen immunotherapy (AIT) remains the cornerstone for managing respiratory allergies, offering long-term symptom relief, disease modification, and prevention of disease progression.
Mongkol Lao-Araya
doaj   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

open access: yesAllergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy   +7 more
wiley   +1 more source

Epicutaneous Immunotherapy with Viaskin Peanut in toddlers: a plain language summary

open access: yesImmunotherapy, 2023
This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years.
David R, Stukus   +6 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy